Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.36 |
| ▸ | PDE4A | P27815 | 8/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19423469 | 0.84 | PDE4D (0.41) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL17353008 | 0.84 | PDE4D (0.41) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL17920816 | 0.84 | PDE4D (0.41) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL17353258 | 0.81 | PDE4D (0.40) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL17353194 | 0.68 | PDE4D (0.42) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL24498739 | 0.66 | SYK (0.46) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL17352923 | 0.65 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL31006004 | 0.65 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL29954690 | 0.65 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4CNTRK1 | |
| SCHEMBL14938173 | 0.64 | HDAC4 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782391-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| EP-3157921-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | Dr. Reddy's Laboratories Ltd. (IN) | 2017-04-26 | — | — | EP | disclosed |
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-09-29 | — | — | US | disclosed |
| US-9394305-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| WO-2015200341-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-30 | — | — | WO | disclosed |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | NTRK1, NTRK3, MUSK | PDE4D 2412/4885PDE4B 2398/4885PDE4A 1748/4885 |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | NTRK1, NTRK3, MUSK | PDE4D 2412/4885PDE4B 2398/4885PDE4A 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.